Cited by 106Liver Disease Diagnosis and TreatmentLiver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease

Open access
Moreno-Fernandez, Maria E., Giles, Daniel A., Stankiewicz, Traci E., Sheridan, Rachel, Karns, Rebekah, Cappelletti, Monica, Lampe, Kristin, Mukherjee, Rajib +7 more·2018·JCI Insight

Abstract

Nonalcoholic fatty liver disease (NAFLD), a metabolic predisposition for development of hepatocellular carcinoma (HCC), represents a disease spectrum ranging from steatosis to steatohepatitis to cirrhosis. Acox1, a rate-limiting enzyme in peroxisomal fatty acid β-oxidation, regulates metabolism, spontaneous hepatic steatosis, and hepatocellular damage over time. However, it is unknown whether Acox1 modulates inflammation relevant to NAFLD pathogenesis or if Acox1-associated metabolic and inflammatory derangements uncover and accelerate potential for NAFLD progression. Here, we show that mice with a point mutation in Acox1 (Acox1 Lampe1 ) exhibited altered cellular metabolism, modified T cell polarization, and exacerbated immune cell inflammatory potential. Further, in context of a brief obesogenic diet stress, NAFLD progression associated with Acox1 mutation resulted in significantly accelerated and exacerbated hepatocellular damage via induction of profound histological changes in hepatocytes, hepatic inflammation, and robust upregulation of gene expression associated with HCC development. Collectively, these data demonstrate that β-oxidation links metabolism and immune responsiveness and that a better understanding of peroxisomal β-oxidation may allow for discovery of mechanisms central for NAFLD progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.93626

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Acox1-KO mice accumulate VLCFAs in their brains but have neither axonal loss nor any neurodegenerative phenotype.

    “Acox1-KO mice accumulate VLCFAs in their brains but have neither axonal loss [267] nor any neurodegenerative phenotype [268].”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [268]

    Citation [268] is attached to the claim that the mice have no neurodegenerative phenotype. The Introduction (page unavailable) calls Acox1-deficiency–associated disease in humans neurodegenerative, but the passages found for “neurodegenerative,” brain VLCFAs, and axonal loss do not assess whether the mice have a neurodegenerative phenotype. The paper’s reported mouse findings concern chiefly liver disease and inflammation. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118 (9):2992-3002. · DOI · Paper page
  2. Strissel KJ, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56 (12):2910-2918. · DOI · Paper page
  3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumula- tion in adipose tissue. J Clin Invest. 2003;112 (12):1796-1808. · DOI · Paper page
  4. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145-171. · DOI · Paper page
  5. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103 (4):1036-1042. · DOI
  6. Li L, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54 (5):1620-1630. · DOI
  7. Giles DA, et al. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent dis- ease modeling. Nat Med. 2017;23(7):829-838. · DOI
  8. Sharifnia T, et al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309(4):G270-G278. · DOI
  9. Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10 (11):637-644. · DOI
  10. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011;11 (12):807-822. · DOI
  11. Harley IT, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology. 2014;59 (5):1830-1839. · DOI
  12. Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Pro- gression. Curr Drug Targets. 2015;16 (12):1315-1323. · DOI
  13. Gu FM, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcino- ma. Mol Cancer. 2011;10:150.
  14. Liao R, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Can- cer Res. 2013;32:3.
  15. Schröder T, et al. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Mol Metab. 2016;5 (4):283-295. · DOI
  16. Berson A, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gas- troenterology. 1998;114 (4):764-774. · DOI
  17. Averill MM, Bornfeldt KE. Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diab Rep. 2009;9 (1):18-25. · DOI
  18. Laine PS, et al. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. Biochem Biophys Res Commun. 2007;358 (1):150-155. · DOI
  19. de Lima-Salgado TM, Alba-Loureiro TC, do Nascimento CS, Nunes MT, Curi R. Molecular mechanisms by which saturated fatty acids modulate TNF-α expression in mouse macrophage lineage. Cell Biochem Biophys. 2011;59 (2):89-97. · DOI
  20. El Hajj HI, et al. The inflammatory response in acyl-CoA oxidase 1 deficiency (pseudoneonatal adrenoleukodystrophy). Endo- crinology. 2012;153 (6):2568-2575. · DOI
  21. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor alpha, and PPA- Ralpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol. 2002;21 (6):1175-1180.
  22. Stauber AJ, et al. Constitutive expression of peroxisome proliferator-activated receptor alpha-regulated genes in dwarf mice. Mol Pharmacol. 2005;67 (3):681-694.
  23. Poll-The BT, et al. A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy). Am J Hum Genet. 1988;42 (3):422-434.
  24. Sheridan R, et al. Lampe1: an ENU-germline mutation causing spontaneous hepatosteatosis identified through targeted exon-enrichment and next-generation sequencing. PLoS One. 2011;6 (7):e21979. · DOI
  25. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445-489. · DOI · Paper page
  26. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS, Hunter CA. IL-6 promotes NK cell production of IL-17 during toxo- plasmosis. J Immunol. 2010;184 (4):1776-1783. · DOI
  27. Goodier MR, Londei M. Lipopolysaccharide stimulates the proliferation of human CD56+CD3-NK cells: a regulatory role of monocytes and IL-10. J Immunol. 2000;165 (1):139-147. · DOI
  28. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195 (3):327-333. · DOI
  29. González-Muniesa P, Milagro FI, Campión J, Martínez JA. Reduction in energy efficiency induced by expression of the uncou- pling protein, UCP1, in mouse liver mitochondria. Int J Mol Med. 2006;17 (4):591-597.
  30. Townsend KL, Tseng YH. Brown fat fuel utilization and thermogenesis. Trends Endocrinol Metab. 2014;25 (4):168-177. · DOI
  31. Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann Hepatol. 2014;13 (5):489-495.
  32. Kawano Y, Nishiumi S, Saito M, Yano Y, Azuma T, Yoshida M. Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease. Curr Drug Targets. 2015;16 (12):1293-1300. · DOI
  33. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19 (29):5250-5269. · DOI · Paper page
  34. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14 (6):433-439. · DOI · Paper page
  35. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. · DOI · Paper page
  36. Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401-435. · DOI
  37. Day CP. From fat to inflammation. Gastroenterology. 2006;130(1):207-210. · DOI
  38. Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1 (1):10. · DOI
  39. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2001;281(6):G1333-G1339. · DOI
  40. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.
  41. Huang J, et al. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J. 2012;26 (2):628-638. · DOI
  42. Gaublomme JT, et al. Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity. Cell. 2015;163 (6):1400-1412. · DOI · Paper page
  43. Bertola A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010;5 (10):e13577. · DOI · Paper page
  44. Vonghia L, et al. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS One. 2015;10 (11):e0143380. · DOI
  45. Gomes AL, et al. Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carci- noma. Cancer Cell. 2016;30 (1):161-175. · DOI · Paper page
  46. Ahmed M, Gaffen SL. IL-17 inhibits adipogenesis in part via C/EBPα, PPARγ and Krüppel-like factors. Cytokine. 2013;61 (3):898-905. · DOI
  47. Huang TT, et al. Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. Hum Mol Genet. 2006;15 (7):1187-1194. · DOI
  48. Kohli R, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010;52 (3):934-944. · DOI
  49. Finkelman F, Morris S, Orekhova T, Sehy D. The in vivo cytokine capture assay for measurement of cytokine production in the mouse. Curr Protoc Immunol. 2003;Chapter 6:Unit 6.28.
  50. Divanovic S, et al. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis. 2012;205 (1):152-161. · DOI
  51. Tschöp MH, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2011;9(1):57-63.
  52. Stemmer K, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int J Obes (Lond). 2015;39 (5):791-797. · DOI
  53. Trapnell C, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7 (3):562-578. · DOI
  54. White T, Bursten S, Federighi D, Lewis RA, Nudelman E. High-resolution separation and quantification of neutral lipid and phospholipid species in mammalian cells and sera by multi-one-dimensional thin-layer chromatography. Anal Biochem. 1998;258 (1):109-117. · DOI

Cited by

Sorted by citations

Authors
Moreno-Fernandez, M. E., Giles, D. A., Stankiewicz, T. E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallese, A., Bridges, J. P., Hogan, S. P., Aronow, B. J., Hoebe, K., & Divanovic, S.
Affiliations
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Cincinnati Children's Hospital Medical Center (US)
  • University Hospital Schleswig-Holstein (DE)
  • University of Cincinnati (US)
Corresponding author
Divanovic, Senad
Venue
JCI Insight
Published
2018-03-22
Volume
3
Issue
6
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2791075083
Cited by
106
References
7
Citations by year
2026: 17 · 2025: 13 · 2024: 13 · 2023: 15 · 2022: 17 · 2021: 12 · 2020: 15 · 2019: 3 · 2018: 1
FWCI
6.05
Type
journal article
Language
en
Open access
Locations
  • JCI Insight (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099222, R01DK099222-02S1)
  • National Institute of Allergy and Infectious Diseases (T32AI118697)
  • U.S. Public Health Service (P30DK078392)
  • American Heart Association (17POST33650045)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
non-alcoholic fatty liver disease, peroxisomal beta-oxidation, ACOX1, hepatic steatosis, hepatocellular carcinoma, liver inflammation, T cell polarization, metabolic inflammation, obesogenic diet, hepatocyte injury, NAFLD progression
MeSH terms
Animals, Adipose Tissue, Brown, Diet, Disease Models, Animal, Fatty Acids, Carcinoma, Hepatocellular, Inflammation, Liver, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Mitochondria, Obesity, Stress, Physiological, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Cytokines, Point Mutation, Disease Progression, Hepatocytes, Acyl-CoA Oxidase, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review